tazobactam has been researched along with brl 28500 in 5 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (brl 28500) | Trials (brl 28500) | Recent Studies (post-2010) (brl 28500) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 237 | 51 | 25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appelbaum, PC; Jacobs, MR; Pankuch, GA | 1 |
| Baughman, R; Boylen, CT; Chan, JC; Charan, NB; Cormier, YC; Erickson, A; Grossman, R; Kirmani, N; Shlaes, DM; Suh, B | 1 |
| Duncanson, FP; Norden, CW; Talan, DA; Tan, JS; Wishnow, RM | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP | 1 |
2 trial(s) available for tazobactam and brl 28500
| Article | Year |
|---|---|
Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; beta-Lactamase Inhibitors; Clavulanic Acids; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam; Ticarcillin | 1994 |
Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.
Topics: Bacteroides Infections; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Tazobactam; Ticarcillin | 1993 |
3 other study(ies) available for tazobactam and brl 28500
| Article | Year |
|---|---|
Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Topics: Ampicillin; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Clavulanic Acids; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Streptococcus pneumoniae; Sulbactam; Tazobactam; Ticarcillin | 1994 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Clavulanic Acids; Drug Synergism; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2021 |